Related references
Note: Only part of the references are listed.cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production
N. Vanlangenakker et al.
CELL DEATH AND DIFFERENTIATION (2011)
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
Derek Yecies et al.
BLOOD (2010)
KIT mutations confer a distinct gene expression signature in core binding factor leukaemia
Sonja C. Lueck et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
RIPK1 is not essential for TNFR1-induced activation of NF-κB
W. W-L Wong et al.
CELL DEATH AND DIFFERENTIATION (2010)
Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response
Christine A. Pratilas et al.
CLINICAL CANCER RESEARCH (2010)
Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
Stephen K. Tahir et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs
Laura M. High et al.
MOLECULAR PHARMACOLOGY (2010)
IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
Mads Gyrd-Hansen et al.
NATURE REVIEWS CANCER (2010)
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2009)
cIAP1, cIAP2, and XIAP Act Cooperatively via Nonredundant Pathways to Regulate Genotoxic Stress-Induced Nuclear Factor-κB Activation
Hyung-Seung Jin et al.
CANCER RESEARCH (2009)
Microtubule dynamics as a target in oncology
April L. Risinger et al.
CANCER TREATMENT REVIEWS (2009)
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
M. Vogler et al.
CELL DEATH AND DIFFERENTIATION (2009)
An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
Glenn Liu et al.
CLINICAL CANCER RESEARCH (2009)
An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently
Julien Viaud et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Inhibitor of apoptosis proteins in hematological malignancies
S. Fulda
LEUKEMIA (2009)
PAK signaling in oncogenesis
P. R. Molli et al.
ONCOGENE (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer
Christine L. Hann et al.
CANCER RESEARCH (2008)
Molecular characterization of acute myeloid leukemia
Konstanze Doehner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination
Mathieu J. M. Bertrand et al.
MOLECULAR CELL (2008)
IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-κB as well as cell survival and oncogenesis
Mads Gyrd-Hansen et al.
NATURE CELL BIOLOGY (2008)
IAP-targeted therapies for cancer
E. C. LaCasse et al.
ONCOGENE (2008)
Core binding factor acute myeloid leukemia
Peter Paschka
SEMINARS IN ONCOLOGY (2008)
IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis
Eugene Varfolomeev et al.
CELL (2007)
Autocrine TNFα signaling renders human cancer cells susceptible to smac-mimetic-induced apoptosis
Sean L. Petersen et al.
CANCER CELL (2007)
Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia
Lars Bullinger et al.
BLOOD (2007)
'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737
X. Lin et al.
ONCOGENE (2007)
Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells
Elizabeth Alli et al.
MOLECULAR PHARMACOLOGY (2007)
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737
Stephen K. Tahir et al.
CANCER RESEARCH (2007)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
Frederick R. Appelbaum et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21):: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16):: A cancer and leukemia group B study
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia
LH Castilla et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain
RBG Ravelli et al.
NATURE (2004)
Cell death: Critical control points
NN Danial et al.
CELL (2004)
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia:: A survey of the German Acute Myeloid Leukemia Intergroup
RF Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
M Milella et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Core binding factor and its role in normal hematopoietic development
NA Speck
CURRENT OPINION IN HEMATOLOGY (2001)
Share Paper
